Johnson & Johnson acquires Halda Therapeutics for $3.05bn
Johnson & Johnson (J&J) has accomplished its acquisition of Halda Therapeutics, a clinical-stage biotechnology firm, for $3.05bn in money.
This transfer brings Halda’s Regulated Induced Proximity Focusing on Chimera (RIPTAC) platform to J&J’s oncology portfolio, supporting the event of oral, focused therapies for a number of stable tumours, together with prostate most cancers.
The acquisition contains HLD-0915, a clinical-stage, once-daily oral remedy for prostate most cancers. This remedy utilises the RIPTAC platform for precision concentrating on of most cancers cells, aiming to deal with resistance mechanisms.
Moreover, the deal provides early-stage candidates for breast, lung, and different tumour sorts, utilizing RIPTAC expertise, to J&J’s pipeline.
The corporate indicated that this platform might probably allow the event of extra focused therapies past oncology.
With the deal closing in 2025, J&J anticipates earnings dilution within the fourth quarter of 2025 and into 2026.
The entire influence on adjusted earnings per share is anticipated to be round $0.20, divided equally between 2025 and 2026, reflecting fees associated to Halda worker fairness, financing, and integration prices.
J&J modern drugs worldwide chairman and govt vp Jennifer Taubert mentioned: “This strategic milestone underscores our dedication to redefining most cancers remedy with breakthrough science and transformative medicines.
“We’re excited to formally welcome the gifted Halda group to J&J and look ahead to working collectively to realize our shared aim of eliminating most cancers.”
J&J modern drugs R&D govt vice-president John Reed mentioned: “Now that we’ve finalised this acquisition, we are going to give attention to advancing the potential of this promising pipeline of novel product candidates and harnessing the highly effective RIPTAC platform to find extra molecules in oncology and past.”
In November 2025, J&J signed a definitive settlement for the acquisition of Halda.
“Johnson & Johnson acquires Halda Therapeutics for $3.05bn” was initially created and printed by Pharmaceutical Know-how, a GlobalData owned model.
The knowledge on this website has been included in good religion for basic informational functions solely. It isn’t supposed to quantity to recommendation on which it’s best to rely, and we give no illustration, guarantee or assure, whether or not specific or implied as to its accuracy or completeness. You have to receive skilled or specialist recommendation earlier than taking, or refraining from, any motion on the idea of the content material on our website.
